

Supplemental Table 1. Treatment-emergent adverse events* by preferred term

	No. of patients (%) (N = 12)
Patients with ≥1 TEAE	11 (91.7)
Grade ≥3 TEAE	7 (58.3)
Serious TEAE	2 (16.7)
TEAE leading to death	0 (0.0)
TEAE leading to treatment discontinuation	1 (8.3)
TEAE leading to dose modification	4 (33.3)
Leading to dose reduction	2 (16.7)
Leading to dose interruption	4 (33.3)
Patients with ≥1 TEAE of special interest	11 (91.7)
Infections	8 (66.7)
Neutropenia	5 (41.7)
Hemorrhage	5 (41.7)
Thrombocytopenia	3 (25.0)
Second primary malignancy	2 (16.7)
Anemia	1 (8.3)
Hypertension	1 (8.3)
Opportunistic infection	1 (8.3)

*A patient could have experienced more than one event. TEAE, treatment-emergent adverse event.